Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 25:9:97-103.
doi: 10.1016/j.mgene.2016.04.005. eCollection 2016 Sep.

Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiple sclerosis risk: A meta-analysis

Jiahe Liu  1 , Xu Liu  1 , Yong Liu  2 , Shimin Deng  3 , Hongbin Huang  1 , Qicong Chen  4 , Weidong Liu  3 , Zunnan Huang  2
Affiliations

Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiple sclerosis risk: A meta-analysis

Jiahe Liu et al. Meta Gene. .

Abstract

Purpose: Multiple sclerosis (MS) is a major demyelinating disease of the central nervous system with a strong genetic component. Previous studies have reported that the association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with the susceptibility to MS. However, the results were inconsistent. Thus, we conducted this meta-analysis to provide a more accurate estimation of the association between any of these polymorphisms and MS risk.

Methods: The PubMed, Embase, Chinese National Knowledge Infrastructure, Wan Fang databases and MSGene were used to search all potentially relevant studies. The odds ratio (OR) with 95% confidence interval (CI) was used to investigate the associations between these three polymorphisms and MS risk.

Results: 16 independent case-control studies from 12 publications were finally included into this meta-analysis. The results showed that EVI5 rs11808092 polymorphism was related with increasing the development of MS under five genetic models (allelic: OR = 1.17, 95% CI = 1.10-1.24, P < 0.01; homozygous: OR = 1.37, 95% CI = 1.18-1.59, P < 0.01; heterozygous: OR = 1.16, 95% CI = 1.07-1.26, P < 0.01; recessive: OR = 1.28, 95% CI = 1.11-1.48, P < 0.01; and dominant: OR = 1.19, 95% CI = 1.11-1.48, P < 0.01). CD58 rs2300747 polymorphism was found to be associated with decreasing MS risk in three genetic models (allelic: OR = 0.86, 95% CI = 0.78-0.94, P < 0.01; heterozygous: OR = 0.85, 95% CI = 0.76-0.94, P < 0.01, and dominant: OR = 0.84, 95% CI = 0.76-0.93, P < 0.01). However, this meta-analysis indicated that CIITA rs3087456 polymorphism was not related to multiple sclerosis.

Conclusions: The mutant alleles of EVI5 rs11808092 polymorphism may increase the susceptibility to MS while those of CD58 rs2300747 polymorphism may decrease MS risk. In addition, CIITA rs3087456 polymorphism might not be associated with MS.

Keywords: CD58 rs2300747; CIITA rs3087456; EVI5 rs11808092; Meta-analysis; Multiple sclerosis; Polymorphisms.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A flow diagram of the process used to select eligible studies.
Fig. 2
Fig. 2
Forest plots of EVI5 rs11808092 polymorphism and MS susceptibility in five genetic models. A: the allelic model (A vs. C); B: the homozygous model (AA vs. CC); C: the heterozygous model (AC vs. CC); D: the recessive model (AA vs. AC + CC); E: the dominant model (AA + AC vs. CC).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Akkad D.A., Jaqiello P., Szyld P., Goedde R., Wieczorek S. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int. J. Immunogenet. 2006;33:59–61. - PubMed
    1. Alcina A., Fernández O., Gonzalez J.R., Catalá-Rabasa A., Fedetz M. Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis. Eur. J. Human Genet. 2010;18:827–831. - PMC - PubMed
    1. Ascherio A., Munger K.L., Lünemann J.D. The initiation and prevention of multiple sclerosis. Nat. Rev. Neurol. 2012;8:602–612. - PMC - PubMed
    1. Bahlo M., Booth D.R., Broadley S.A., Brown M.A., Foote S.J. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 2009;41:824–828. - PubMed
    1. Barcellos L., Oksenberg J., Begovich A., Martin E., Schmidt S. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 2003;72:710–716. - PMC - PubMed

LinkOut - more resources